statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Presentation to highlight therapeutic potential of Athira's small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease...

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Stryker (SYK) one of those stocks right now? A quick glance at the company's...

Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?

This indicator may be signaling that ATHA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Athira Pharma (ATHA, $3.58) entered Downtrend as Momentum indicator drops below 0 level on Mar 08, 2024

Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases such as Parkinson's disease...

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD  2024 International Conference

Athira Pharma, Inc. (ATHA) shares are declining more than 3 percent on Friday morning trade after reaching a new year-to-date high at Thursday's close. There have been no stock-specific news today...

Athira Pharma Shares Slide

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Athira Pharma reports FY23 EPS ($3.09), consensus ($3.33)

Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease; topline data expected in second half of 2024 On track...

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

This is a signal that ATHA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Athira Pharma (ATHA, $3.71) RSI Indicator left the overbought zone on February 21, 2024

Athira Pharma (ATHA, $3.92) RSI Indicator left the overbought zone on February 20, 2024

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Volume	75,323.00
52-Wk High	$4.30
52-Wk Low	$1.33

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.80	--	--	N/A
Q4'23	-$0.84	-$0.71	15.24%	BEAT
Q3'23	-$0.81	-$0.87	-6.81%	MISSED
Q2'23	-$0.78	-$0.78	0.52%	BEAT
Q1'23	-$0.62	-$0.73	-17.15%	MISSED

ATHA Athira Pharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals